{"id":28212,"date":"2014-08-13T10:47:14","date_gmt":"2014-08-13T14:47:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28212"},"modified":"2014-08-13T10:47:14","modified_gmt":"2014-08-13T14:47:14","slug":"aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212","title":{"rendered":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/13\/2014 (wallstreetpr) \u2013 <b>Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)<\/b> has announced the pricing of <a href=\"http:\/\/finance.yahoo.com\/news\/aegerion-pharmaceuticals-inc-prices-300-124709387.html\" target=\"_blank\">$300 million <\/a>of 2% convertible notes that are due in 2019. The pharmaceutical company has also availed an option for initial purchasers to purchase an additional $45 million aggregate principal amount to cover for any form of over-allotments. The conversion rates of the notes stands at 24.2866 shares of Aegerion Pharmaceuticals\u00a0 common stock for every $1,000 principal amount notes, equivalent to initial conversion price of approximately $41.175 per share of common stock.<\/p>\n<p style=\"text-align: justify;\"><b>Offering To Close On Friday<\/b><\/p>\n<p style=\"text-align: justify;\">The conversion rate represents a 35% premium on the company\u2019s closing stock price of $30.50 as of Monday August 11.\u00a0Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has also stated that the conversion rate may be subject to adjustment during distribution of dividends or stock splits. The company plans to settle conversions of the convertible notes by delivering its common stock. The transaction is set to close on August 15, 2012 subject to customary closing conditions.<\/p>\n<p style=\"text-align: justify;\">Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has also entered into a privately negotiated convertible note hedge transactions with initial purchasers a move that is expected not to affect dilution or offset any form of cash payment.<\/p>\n<p style=\"text-align: justify;\"><b>Uses of Net Proceeds<\/b><\/p>\n<p style=\"text-align: justify;\">The company has also entered a similar transaction with hedge counterparties. Initial purchasers have also been given&#8217; the option of exercising the option of purchasing additional convertible notes. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) plans to enter into addition transactions with hedge counterparties on warrant transactions and additional note hedge.<\/p>\n<p style=\"text-align: justify;\">Net proceeds from the offering, as well as the entrance into warrant transactions, are to be used to bolster Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)\u2019s working capital as well as cater for other general corporate expenses. Part of the money could be used to finance possible acquisition or future investments in businesses technologies or for the repurchase of approximately $35 million outstanding common stock.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/13\/2014 (wallstreetpr) \u2013 Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has announced the pricing of $300 million of 2% convertible notes that are due in 2019. [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":16153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[7879,2375,2376],"stock_ticker":[],"class_list":["post-28212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-aegerion-pharmaceuticals-inc","tag-aegerion-pharmaceuticals-inc-nasdaqaegr","tag-nasdaqaegr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/13\/2014 (wallstreetpr) \u2013 Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has announced the pricing of $300 million of 2% convertible notes that are due in 2019. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-13T14:47:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"530\" \/>\n\t<meta property=\"og:image:height\" content=\"298\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings\",\"datePublished\":\"2014-08-13T14:47:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg\",\"keywords\":[\"Aegerion Pharmaceuticals Inc.\",\"Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)\",\"NASDAQ:AEGR\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\",\"name\":\"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg\",\"datePublished\":\"2014-08-13T14:47:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg\",\"width\":530,\"height\":298},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212","og_locale":"en_US","og_type":"article","og_title":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings  - Wall Street PR","og_description":"Boston, MA 08\/13\/2014 (wallstreetpr) \u2013 Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has announced the pricing of $300 million of 2% convertible notes that are due in 2019. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-13T14:47:14+00:00","og_image":[{"width":530,"height":298,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings","datePublished":"2014-08-13T14:47:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg","keywords":["Aegerion Pharmaceuticals Inc.","Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)","NASDAQ:AEGR"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212","url":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212","name":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg","datePublished":"2014-08-13T14:47:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Aegerion-Pharmaceuticals-Inc..jpg","width":530,"height":298},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aegerion-pharmaceuticals-inc-nasdaqaegr-prices-its-300-million-convertible-senior-notes-offerings-28212#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Prices Its $300 Million Convertible Senior Notes Offerings"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28212"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16153"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28212"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}